IDO1 and myeloid sarcoma: Some studies demonstrated low TRP levels in the blood and CSF of patients in the chronic phase of MS, confirming KP activation [74], while patients with relapsing–remitting MS (RRMS) were found to have increased IDO-1 expression with a corresponding increase in serum KYN and N-formyl kynurenine levels [30,75].